Bicara Therapeutics' lead candidate, ficerafusp alfa, targets EGFR and TGF-beta in tumors, showing promise in hard-to-treat cancers like Head and Neck Squamous Cell Carcinoma. Bicara's financial ...

Bicara Therapeutics Inc. announced multiple presentations at the AACR Annual Meeting 2025 regarding their leading therapy, ficerafusp alfa, a novel bifunctional antibody targeting EGFR and TGF-β for ...

BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients ...

Bicara Therapeutics Inc., led by Dr. Claire Mazumdar, recently IPO'd with a promising bifunctional antibody, ficerafusp alfa, targeting head and neck cancer. Ficerafusp alfa shows impressive interim ...

Ficerafusp alfa is a first-in-class bifunctional antibody that combines two clinically validated targets: an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that ...

Ficerafusp alfa, a bifunctional antibody, targets EGFR and TGF-β, potentially offering anti-tumor activity in HNSCC patients. The FORTIFI-HN01 trial evaluates ficerafusp alfa with Keytruda in ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Bicara Therapeutics, a clinical-stage biotechnology company developing dual-action biologics to elicit a potent and durable immune response, today announced that it ...

Several analysts are hailing Merus as the sure winner in the race to a new treatment for head and neck squamous cell carcinoma (HNSCC). But the chase is still in its early days and is likely too soon ...